|2010.09.01||ReproCELL announces new line of products in neuronal research using human iPS cells
Since April 2009, ReproCELL has been manufacturing iPS cell-derived cardiomyocytes for drug toxicity testing as the world’s first drug discovery support business provider founded on iPS cells. The prospective new offering of neuronal cells is the second line of products to be introduced by the company, and is a considerable expansion of their scope of business. ReproCELL will be the first in the world to offer iPS cell derived neuronal cells, and, more specifically, will provide dopaminergic neurons, motor neurons, and cerebral nerves.
|2010.07.01||MEDIAReproCELL featured in Genetic Engineering & Biotechnology News
An article in Genetic Engineering & Biotechnology News, “Pharma’s R&D Focus Shifting to Stem Cells -Investors’ Interest in These Cells Increases as Scientists Continue to Unleash Their Potential” introduces ReproCELL’s new cardiotoxicity assay using iPSCs, QTempo, as well as its neural stem cell research. Read the article